{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:05:49Z","timestamp":1781939149840,"version":"3.54.5"},"reference-count":214,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes corticosteroids and rituximab, is associated with adverse effects as well as treatment failures, and relapses are common. Subsequent lines of therapy are associated with higher rates of toxicity, and some patients remain refractory to currently available treatments. Novel therapies have become promising for this vulnerable population. In this review, we will discuss the mechanism of action, existing data, and ongoing clinical trials of current novel therapies for AIHA, including B-cell-directed therapy, phagocytosis inhibition, plasma cell-directed therapy, and complement inhibition.<\/jats:p>","DOI":"10.3390\/pharmaceutics14051035","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T05:10:32Z","timestamp":1652332232000},"page":"1035","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Development of New Drugs for Autoimmune Hemolytic Anemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Zhengrui","family":"Xiao","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Hematology-Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Murakhovskaya","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Hematology-Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.10062","article-title":"Autoimmune hemolytic anemia","volume":"69","author":"Gehrs","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00508-008-0945-1","article-title":"Diagnosis and treatment of autoimmune haemolytic anaemias in adults: A clinical review","volume":"120","author":"Valent","year":"2008","journal-title":"Wien Klin. Wochenschr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The Changing Landscape of Autoimmune Hemolytic Anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"Jager","year":"2020","journal-title":"Blood Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: Clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: Results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: A multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1136\/bmj.282.6281.2023","article-title":"Autoimmune haemolysis: An 18-year study of 865 cases referred to a regional transfusion centre","volume":"282","author":"Sokol","year":"1981","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000488753","article-title":"A Comprehensive Diagnostic Algorithm for Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Reveals the Relative Ratio of Three Mechanisms in a Single Laboratory","volume":"140","author":"Kamesaki","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Barcellini, W., Zaninoni, A., Giannotta, J.A., and Fattizzo, B. (2020). New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123859"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): An open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"Roth","year":"2018","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Audia, S., Bach, B., Samson, M., Lakomy, D., Bour, J.B., Burlet, B., Guy, J., Duvillard, L., Branger, M., and Leguy-Seguin, V. (2018). Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207218"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/bloodadvances.2019000476","article-title":"Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease","volume":"3","author":"Bylsma","year":"2019","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1172\/JCI106544","article-title":"Quantitative immunology of immune hemolytic anemia: II. The relationship of cell-bound antibody to hemolysis and the effect of treatment","volume":"50","author":"Rosse","year":"1971","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.4049\/jimmunol.131.3.1240","article-title":"Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy","volume":"131","author":"Fries","year":"1983","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00508-015-0863-y","article-title":"Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia","volume":"128","author":"Kulpa","year":"2016","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/rheumatology\/ken071","article-title":"A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans\u2019 syndrome: Immunological analysis of B cells, T cells and cytokines","volume":"47","author":"Tamimoto","year":"2008","journal-title":"Rheumatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminhematol.2010.01.010","article-title":"Rituximab in autoimmune hematologic diseases: Not just a matter of B cells","volume":"47","author":"Stasi","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2796.2009.02126.x","article-title":"Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: A Belgian retrospective multicentric study","volume":"266","author":"Dierickx","year":"2009","journal-title":"J. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ajh.21341","article-title":"Efficacy and safety of rituximab in adults\u2019 warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases","volume":"84","author":"Bussone","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.12486","article-title":"A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia","volume":"163","author":"Maung","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00277-010-0997-y","article-title":"Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia","volume":"89","author":"Penalver","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2018-12-885228","article-title":"Low-dose rituximab in autoimmune hemolytic anemia: 10 years after","volume":"133","author":"Fattizzo","year":"2019","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/pgmj.41.482.748","article-title":"Splenic Mechanisms in the Pathogenesis of Anaemia","volume":"41","author":"Bowdler","year":"1965","journal-title":"Postgrad. Med. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.amjsurg.2012.05.030","article-title":"Outcomes and complications after splenectomy for hematologic disorders","volume":"204","author":"Patel","year":"2012","journal-title":"Am. J. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1096-8652(199906)61:2<98::AID-AJH4>3.0.CO;2-G","article-title":"Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease","volume":"61","author":"Akpek","year":"1999","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00464-003-9092-y","article-title":"Long-term outcome after laparoscopic splenectomy related to hematologic diagnosis","volume":"18","author":"Balague","year":"2004","journal-title":"Surg. Endosc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jinf.2001.0904","article-title":"Risk of infection and death among post-splenectomy patients","volume":"43","author":"Bisharat","year":"2001","journal-title":"J. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","article-title":"Risk for hospital contact with infection in patients with splenectomy: A population-based cohort study","volume":"151","author":"Thomsen","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: Old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: Implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000205048","article-title":"Efficacy of danazol in hematologic disorders","volume":"84","author":"Ahn","year":"1990","journal-title":"Acta Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: A multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in Cold Agglutinin Disease","volume":"384","author":"Roth","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMra2033982","article-title":"Autoimmune Hemolytic Anemias","volume":"385","author":"Berentsen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: A prospective study of 20 patients","volume":"47","author":"Schollkopf","year":"2006","journal-title":"Leuk. Lymphoma."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: A phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: A crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1189\/jlb.72.6.1092","article-title":"Signal transduction during Fc receptor-mediated phagocytosis","volume":"72","author":"Rosales","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.1500461","article-title":"Syk tyrosine kinase is critical for B cell antibody responses and memory B cell survival","volume":"194","author":"Ackermann","year":"2015","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: Modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0092-8674(87)90168-1","article-title":"Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity","volume":"50","author":"Kaplan","year":"1987","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: An updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1038\/onc.2008.244","article-title":"Class I PI3K in oncogenic cellular transformation","volume":"27","author":"Zhao","year":"2008","journal-title":"Oncogene"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: Navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3389\/fimmu.2017.00747","article-title":"The Selective Phosphoinoside-3-Kinase p110delta Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation","volume":"8","author":"Chiu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000495779","article-title":"Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia","volume":"141","author":"Feld","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1002\/ajh.25480","article-title":"Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: A study from the FILO group","volume":"94","author":"Quinquenel","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Ramchandren","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase delta Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"107904","DOI":"10.1016\/j.intimp.2021.107904","article-title":"The PI3Kdelta inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjgren\u2019s syndrome","volume":"98","author":"Scuron","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_73","unstructured":"Barcellini, W., Terriou, L., Pane, F., Patriarca, A., Butler, K., Moran, S., Wei, S., and J\u00e4ger, U. (2021, January June). Efficacy and safety results from an open-label phase 2 stydy of parsiclisib for the treatment of autoimmune hemolytic anemia. Proceedings of the European Hematology Association, Available online: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/325445\/wilma.barcellini.efficacy.and.safety.results.from.an.open-label.phase.2.study.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1."},{"key":"ref_74","unstructured":"U.S. National Library of Medicine (2022). Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1038\/bcj.2017.5","article-title":"Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study","volume":"7","author":"Montillo","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000456002","article-title":"Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma","volume":"10","author":"Galinier","year":"2017","journal-title":"Case Rep. Oncol."},{"key":"ref_77","first-page":"412","article-title":"Ibrutinib treatment for 2 cases of relapsed\/refractory autoimmune hemolytic anemia: A pilot study","volume":"41","author":"Fang","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-139131","article-title":"Effective Treatment of Cold Agglutinin Disease\/Cold Agglutinin Syndrome with Ibrutinib: An International Case Series","volume":"136","author":"Jalink","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tmrv.2015.09.001","article-title":"Sirolimus for Refractory Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review of the Treatment of Post-Transplant Autoimmune Hemolytic Anemia","volume":"30","author":"Park","year":"2016","journal-title":"Transfus. Med. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/petr.12101","article-title":"Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor","volume":"17","author":"Acquazzino","year":"2013","journal-title":"Pediatr. Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.exphem.2020.08.001","article-title":"Sirolimus is effective for primary relapsed\/refractory autoimmune cytopenia: A multicenter study","volume":"89","author":"Li","year":"2020","journal-title":"Exp. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: Results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1155\/2001\/28962","article-title":"Role of Bruton\u2019s tyrosine kinase in B cell development","volume":"8","author":"Maas","year":"2001","journal-title":"Dev. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"694853","DOI":"10.3389\/fimmu.2021.694853","article-title":"Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors","volume":"12","author":"Zain","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1749-6632.1995.tb55802.x","article-title":"The role of Bruton\u2019s tyrosine kinase in B-cell development and function in mice and man","volume":"764","author":"Khan","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","article-title":"The Role of Bruton\u2019s Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Messex, J.K., and Liou, G.Y. (2021). Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option. Cancers, 13.","DOI":"10.3390\/cancers13092198"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton\u2019s Tyrosine Kinase: An Emerging Key Player in Innate Immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton\u2019s tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects","volume":"9","author":"Estupinan","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V128.22.1259.1259","article-title":"Inhibitors of Bruton\u2019s Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia","volume":"128","author":"Rogers","year":"2016","journal-title":"Blood"},{"key":"ref_94","first-page":"483","article-title":"Ibrutinib (imbruvica): A novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar","year":"2014","journal-title":"Phys. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton\u2019s tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhang, D., Gong, H., and Meng, F. (2021). Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules, 26.","DOI":"10.3390\/molecules26164907"},{"key":"ref_98","unstructured":"U.S. National Library of Medicine (2020). Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia (ISRAEL)."},{"key":"ref_99","unstructured":"U.S. National Library of Medicine (2020). The Safety and Efficacy of Ibrutinib in Refractory\/Relapsed Autoimmune Hemolytic Anemia."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"668162","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: Updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"ref_102","unstructured":"U.S. National Library of Medicine (2021). Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2021-145128","article-title":"Updated Phase I\/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed\/Refractory Immune Thrombocytopenia","volume":"138","author":"Kuter","year":"2021","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2021-144504","article-title":"LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia","volume":"138","author":"Kuter","year":"2021","journal-title":"Blood"},{"key":"ref_106","unstructured":"U.S. National Library of Medicine (2022). Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA)."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3892\/ol.2014.2608","article-title":"mTOR pathway: A current, up-to-date mini-review (Review)","volume":"8","author":"Zarogoulidis","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR Pathway in Angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fimmu.2012.00228","article-title":"Akt and mTOR in B Cell Activation and Differentiation","volume":"3","author":"Limon","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: Its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant. Proc."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"611690","DOI":"10.3389\/fonc.2020.611690","article-title":"The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside","volume":"10","author":"Feng","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/JBM.S190327","article-title":"Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: Current perspectives","volume":"10","author":"Barcellini","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2017.12.782","article-title":"Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients","volume":"24","author":"Kruizinga","year":"2018","journal-title":"Biol. Blood Marrow. Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES): A Single Institution\u2019s Experience","volume":"39","author":"Jasinski","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","article-title":"Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome","volume":"145","author":"Teachey","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_117","unstructured":"U.S. National Library of Medicine (2020). Sirolimus Combined with ATRA for the Treatment of Auto-Immune Anemia."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"18563","DOI":"10.1073\/pnas.1009048107","article-title":"Syk is a dual-specificity kinase that self-regulates the signal output from the B-cell antigen receptor","volume":"107","author":"Heizmann","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4049\/jimmunol.170.2.846","article-title":"A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation","volume":"170","author":"Sedlik","year":"2003","journal-title":"J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1165\/rcmb.2005-0298OC","article-title":"Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation","volume":"34","author":"Matsubara","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2217\/imt-2020-0215","article-title":"Fostamatinib: A review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia","volume":"12","author":"Newland","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study","volume":"97","author":"Kuter","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-140469","article-title":"Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study","volume":"136","author":"Cooper","year":"2020","journal-title":"Blood"},{"key":"ref_129","unstructured":"U.S. National Library of Medicine (2021). A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M113.537563","article-title":"Structural insights into neonatal Fc receptor-based recycling mechanisms","volume":"289","author":"Oganesyan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2016.03.007","article-title":"A comprehensive review of the neonatal Fc receptor and its application in drug delivery","volume":"161","author":"Martins","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"MAbs"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The Neonatal Fc Receptor (FcRn): A Misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.jid.2021.06.035","article-title":"Targeting the FcRn: A Novel Approach to the Treatment of Pemphigus","volume":"141","author":"Nelson","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_139","unstructured":"U.S. National Library of Medicine (2020). A Safety Study of SYNT001 in Participants with Warm Autoimmune Hemolytic Anemia (WAIHA)."},{"key":"ref_140","unstructured":"U.S. National Library of Medicine (2022). Subcutaneous ALXN1830 in Adult Participants with Warm Autoimmune Hemolytic Anemia."},{"key":"ref_141","unstructured":"U.S. National Library of Medicine (2020). ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_143","unstructured":"U.S. National Library of Medicine (2021). A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia (ADVANCE SC+)."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V126.23.3472.3472","article-title":"M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto\/Allo-Immune Disease","volume":"126","author":"Ling","year":"2015","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Guptill, J., Antozzi, C., Bril, V., Gamez, J., Meuth, S.G., Blanco, J.L.M., Nowak, R.J., Quan, D., Sevilla, T., and Szczudlik, A. (2021). Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis. Neurology, 96.","DOI":"10.1212\/WNL.96.15_supplement.2157"},{"key":"ref_147","unstructured":"U.S. National Library of Medicine (2022). Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia."},{"key":"ref_148","unstructured":"U.S. National Library of Medicine (2022). Post-trial Access for Nipocalimab in Participants with Warm Autoimmune Hemolytic Anemia (wAIHA)."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"498.e491","DOI":"10.1016\/j.ajog.2019.02.058","article-title":"M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model","volume":"220","author":"Roy","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_150","unstructured":"U.S. National Library of Medicine (2022). A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Keller, C.W., Pawlitzki, M., Wiendl, H., and Lunemann, J.D. (2021). Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115755"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079","article-title":"RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079)","volume":"92","author":"Collins","year":"2019","journal-title":"Neurology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-021-01663-9","article-title":"2021 update on thyroid-associated ophthalmopathy","volume":"45","author":"Neag","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_154","unstructured":"U.S. National Library of Medicine (2021). To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA)."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mahevas","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00602-3","article-title":"Role of proteasomes in cellular regulation","volume":"267","author":"Konstantinova","year":"2008","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma","volume":"2","author":"Morgan","year":"2006","journal-title":"Ther. Clin. Risk. Manag."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","article-title":"Proteasome inhibitor bortezomib for the treatment of multiple myeloma","volume":"20","author":"Cavo","year":"2006","journal-title":"Leukemia"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/pbc.25172","article-title":"Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant","volume":"61","author":"Mehta","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Wong, D., Thomas, W., Butler, A., and Sharkey, L. (2021). Bortezomib for treatment-refractory autoimmune haemolytic anaemia following multivisceral transplantation. BMJ Case Rep., 14.","DOI":"10.1136\/bcr-2021-241634"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/trf.12815","article-title":"Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: Report of a case and review of literature","volume":"55","author":"Hosoba","year":"2015","journal-title":"Transfusion"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1080\/10428194.2017.1421759","article-title":"Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib","volume":"59","author":"Cao","year":"2018","journal-title":"Leuk. Lymphoma."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e14045","DOI":"10.1111\/petr.14045","article-title":"Anti-plasma cell treatment in refractory autoimmune hemolytic anemia in a child with multivisceral transplant","volume":"25","author":"Ghobrial","year":"2021","journal-title":"Pediatr. Transplant."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e13700","DOI":"10.1111\/petr.13700","article-title":"Bortezomib for autoimmune hemolytic anemia after intestinal transplantation","volume":"24","author":"Knops","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bjh.16009","article-title":"Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia","volume":"187","author":"Fadlallah","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","article-title":"Bortezomib-based antibody depletion for refractory autoimmune hematological diseases","volume":"1","author":"Ratnasingam","year":"2016","journal-title":"Blood Adv."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"20406207211046428","DOI":"10.1177\/20406207211046428","article-title":"Bortezomib in autoimmune hemolytic anemia and beyond","volume":"12","author":"Pasquale","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e28679","DOI":"10.1097\/MD.0000000000028679","article-title":"Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia","volume":"101","author":"Yao","year":"2022","journal-title":"Medicine"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ajh.21950","article-title":"Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide","volume":"86","author":"Danchaivijitr","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00277-020-03976-w","article-title":"Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia","volume":"99","author":"Chen","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1007\/s00277-020-04135-x","article-title":"Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia","volume":"100","author":"Ames","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_175","unstructured":"U.S. National Library of Medicine (2021). Single-Dose Anti-CD20 Antibody with Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia (RRAIHA01)."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Benfaremo, D., and Gabrielli, A. (2019). Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?. Cells, 9.","DOI":"10.3390\/cells9010077"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16171","article-title":"Post-allogeneic transplant Evans syndrome successfully treated with daratumumab","volume":"187","author":"Blennerhassett","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e28591","DOI":"10.1002\/pbc.28591","article-title":"Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: Response to therapy and late effects","volume":"67","author":"Koo","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e28010","DOI":"10.1002\/pbc.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia","volume":"67","author":"Shadur","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia","volume":"100","author":"Jain","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","article-title":"The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.17655","article-title":"Daratumumab in rituximab-refractory autoimmune haemolytic anaemia","volume":"194","author":"Rieger","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_189","unstructured":"U.S. National Library of Medicine (2022). The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia (DARA-AIHA)."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-019-0198-4","article-title":"Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma","volume":"9","author":"Martin","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_193","unstructured":"U.S. National Library of Medicine (2022). Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults with Warm Autoimmune Hemolytic Anemia (wAIHA)."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and precision medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"Roth","year":"2009","journal-title":"Blood"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00277-013-1800-7","article-title":"Long-term response of refractory primary cold agglutinin disease to eculizumab therapy","volume":"93","author":"Gupta","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-018-3521-4","article-title":"High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease","volume":"98","author":"Makishima","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"123","author":"Risitano","year":"2014","journal-title":"Blood"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_202","unstructured":"(2021, May 18). FDA Approves New Treatment for Adults with Serious Rare Blood Disease, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-adults-serious-rare-blood-disease."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood-2018-99-119468","article-title":"Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Autoimmune Hemolytic Anemia (AIHA)","volume":"132","author":"Grossi","year":"2018","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood-2018-99-119468","article-title":"Inhibition of C3 with APL-2 Controls Hemolysis and Increases Hemoglobin Levels in Subjects with Autoimmune Hemolytic Anemia (AIHA)","volume":"132","author":"Grossi","year":"2019","journal-title":"Blood"},{"key":"ref_205","unstructured":"U.S. National Library of Medicine (2022). Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients with Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V118.21.716.716","article-title":"C1-Inhibitor Rescues Red Blood Cells From Complement Mediated Destruction in Autoimmune Hemolytic Anemia","volume":"118","author":"Wouters","year":"2011","journal-title":"Blood"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: A first-in-human trial","volume":"133","author":"Jager","year":"2019","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","article-title":"Inhibition of complement C1s in patients with cold agglutinin disease: Lessons learned from a named patient program","volume":"4","author":"Gelbenegger","year":"2020","journal-title":"Blood Adv."},{"key":"ref_209","unstructured":"U.S. National Library of Medicine (2022). A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants with Primary Cold Agglutinin Disease without A Recent History of Blood Transfusion (Cadenza)."},{"key":"ref_210","first-page":"104","article-title":"C1S-Targeted inhibition of classical complement pathway by sutimlimab in cold agglutinin disease (CAD): Efficacy and safety results from the randomized, placebo (PBO)-controlled phase 3 cadenza study","volume":"5","author":"Roth","year":"2021","journal-title":"Hemasphere"},{"key":"ref_211","unstructured":"U.S. National Library of Medicine (2020). A Safety and Tolerability Study of BIVV020 in Adults with Cold Agglutinin Disease."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.V128.22.1265.1265","article-title":"ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease","volume":"128","author":"Gertz","year":"2016","journal-title":"Blood"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood-2021-153866","article-title":"Evidence of Classical Complement Pathway Involvement in a Subset of Patients with Warm Autoimmune Hemolytic Anemia","volume":"138","author":"Teigler","year":"2021","journal-title":"Blood"},{"key":"ref_214","unstructured":"U.S. National Library of Medicine (2020). Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Subjects with Warm Autoimmune Hemolytic Anemia (wAIHA)."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/1035\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:09:12Z","timestamp":1760137752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/5\/1035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":214,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["pharmaceutics14051035"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14051035","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]}}}